细针穿刺标本Midkine检测在甲状腺微小乳头状癌中的临床意义

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (0 KB) HTML (36 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨细针穿刺标本Midkine检测在甲状腺微小乳头状癌中的临床意义。方法选取2014年8月～2017年5月我院收治的50例甲状腺微小乳头状癌患者、30例结节性甲状腺肿患者的术中细针穿刺标本作为研究对象，观察两类病理类型免疫细胞化学技术检测Midkine的表达。结果甲状腺微小乳头状癌细针穿刺标本Midkine的表达明显高于结节性甲状腺肿，差异有统计学意义（P＜0.01）。有淋巴结转移甲状腺微小乳头状癌患者的细针穿刺标本Midkine表达阳性率高于无淋巴结转移患者，差异有统计学意义（P＜0.05）。结论检测细针穿刺标本Midkine的表达可为甲状腺微小乳头状癌的正确诊断和淋巴结转移预测提供帮助。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄东航
	陈旭
	陈兴
	曾焕虹

关键词 ：中期生长因子, 甲状腺癌, 肿瘤标志物, 免疫细胞化学

Abstract：Objective To investigate the clinical significance of fine-needle aspiration specimen Midkine detection in papillary thyroid microcarcinoma.Methods Fine-needle aspiration specimens from 50 patients with papillary thyroid microcarcinoma and 30 patients with thyroid nodular goiter who were admitted to our hospital and underwent surgery from August 2014 to May 2017 were selected as objects.Immunocytochemical expression of Midkine was observed in fine-needle aspiration specimens from above patients.Results Fine-needle aspiration specimen Midkine expression of papillary thyroid microcarcinoma was significantly higher than that of thyroid nodular goiter,and the difference was statistically significant(P＜0.01).The positive rate of Midkine expression in patients with lymph node metastasis of papillary thyroid microcarcinoma was higher than that of patients without lymph node metastasis,and the difference was statistically significant(P＜0.05).Conclusion The detection of fine-needle aspiration specimen Midkine is helpful in the diagnosis of papillary thyroid microcarcinoma and the prediction of lymph node metastasis.

Key words： Midkine Thyroid carcinoma Tumor marker Immunocytochemistry

基金资助:福建省卫生计生委医学创新课题（2015-CXB-2）；福建省科学技术厅引导性项目（2015Y0007）

作者简介: 黄东航（1969-），男，硕士，主任医师，研究方向：甲状腺、乳腺肿瘤的临床与基础研究

引用本文:

黄东航;陈旭;陈兴;曾焕虹. 细针穿刺标本Midkine检测在甲状腺微小乳头状癌中的临床意义[J]. 中国当代医药, 2018, 25(21): 117-119.
HUANG Dong-hang;CHEN Xu;CHEN Xing;ZENG Huan-hong. Clinical significance of fine-needle aspiration specimen Midkine detection in papillary thyroid microcarcinoma. 中国当代医药, 2018, 25(21): 117-119.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I21/117

[1]	Kitahara CM，Sosa JA.The changing incidence of thyroid cancer[J].Nat Rev Endocrinol，2016，12（11）：646.
[2]	Wiltshire JJ，Drake TM，Uttley L，et al.Systematic review of trends in the incidence rates of thyroid cancer[J].Thyroid，2016，26（11）：1541-1552.
[3]	Lim H，Devesa SS，Sosa JA，et al.Trends in thyroid cancer incidence and mortality in the United States，1974-2013[J].JAMA，2017，317（13）：1338-1348.
[4]	Oda H，Miyauchi A，Ito Y，et al.Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery[J].Thyroid，2016，26（1）：150-155.
[5]	Li D，Gao M，Li X，et al.Molecular aberrance in papillary thyroid microcarcinoma bearing high aggressiveness：identifying a “tibetan mastiff dog” from puppies[J].J Cell Biochem，2016，117（7）：1491-1496.
[6]	Leboulleux S，Tuttle RM，Pacini F，et al.Papillary thyroid microcarcinoma：time to shift from surgery to active surveillance？[J].Lancet Diabetes Endocrinol，2016，4（11）：933-942.
[7]	Lee J，Soh EY.Current guidelines for fine needle aspiration of thyroid nodules[J].Korean J Endocrine Surg，2015，15（1）：1-5.
[8]	Zevallos JP，Hartman CM，Kramer JR，et al.Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration：a study of the Veterans Affairs health care system[J].Cancer，2015，121（5）：741-746.
[9]	Eszlinger M，Lau L，Ghaznavi S，et al.Molecular profiling of thyroid nodule fine-needle aspiration cytology[J].Nat Rev Endocrinol，2017，13（7）：415.
[10]	戎荣，吴妍，姚青，等.甲状腺细针穿刺检查2043例细胞病理学分析[J].中华病理学杂志，2016，45（6）：368-371.
[11]	Lee YH，Baek JH，Jung SL，et al.Ultrasound-guided fine needle aspiration of thyroid nodules：a consensus statement by the Korean Society of Thyroid Radiology[J].Korean J Radiol，2015，16（2）：391-401.
[14]	Cabanillas ME，Mcfadden DG，Durante C.Thyroid cancer[J].The Lancet，2016，388（10061）：2783-2795.
[12]	Shao H，Yu X，Wang C，et al.Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer[J].Endocrine，2014，46（2）：285-291.
[13]	Choi YW，Kim YH，Lee J，et al.Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma[J].Human pathology，2015，46（10）：1557-1565.
[15]	Chiosea S，Asa SL，Berman MA，et al.Template for reporting results of biomarker testing of specimens from patients with thyroid carcinoma[J].Arch Pathol Lab Med，2016，141（4）：559-563.
[16]	Muramatsu T.Structure and function of midkine as the basis of its pharmacological effects[J].Br J Pharmacol，2014，171（4）：814-826.
[17]	Jones DR.Measuring midkine：the utility of midkine as a biomarker in cancer and other diseases[J].Br J Pharmacol，2014，171（12）：2925-2939.
[18]	Maeda S，Shinchi H，Kurahara H，et al.Clinical significance of Midkine expression in pancreatic head carcinoma[J].Br J Cancer，2007，97（3）：405-408.
[19]	Zhao ZQ，Yang S，Lu HS.Expression of Midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival[J].Mol Med Rep，2012，5（2）：415-419.
[20]	Jham BC，Costa NL，Silva JM，et al.Midkine expression in oral squamous cell carcinoma and leukoplakia[J].J Oral Pathol Med，2012，41（1）：21-26.